MAP2K1 and neuroblastoma: To evaluate whether gene expression of RAS/MAPK pathway members was associated with neuroblastoma patient outcomes, we evaluated the associations of NF1 and MEK1/2 gene expression with neuroblastoma patient outcomes using results from microarray analyses of neuroblastoma tumors.